Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare... Keep Reading...
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy... Keep Reading...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive... Keep Reading...
Review Highlights High Grade Bismuth Intercepts at Orlando

Review Highlights High Grade Bismuth Intercepts at Orlando

CuFe Limited (CUF:AU) has announced Review Highlights High Grade Bismuth Intercepts at OrlandoDownload the PDF here. Keep Reading...
Cloncurry Gold Project Acquisition To Close In November

Cloncurry Gold Project Acquisition To Close In November

AuKing Mining (AKN:AU) has announced Cloncurry Gold Project Acquisition To Close In NovemberDownload the PDF here. Keep Reading...
Maiden Drilling Results from Mt Solitary

Maiden Drilling Results from Mt Solitary

Mount Hope Mining (MHM:AU) has announced Maiden Drilling Results from Mt SolitaryDownload the PDF here. Keep Reading...
Bold Ventures Highlights Burchell Gold Copper Project News

Bold Ventures Highlights Burchell Gold Copper Project News

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to highlight news from the area of its Burchell Gold and Copper Property ("Burchell" or the "Property"), while anticipating channel sampling results from its recent mechanical stripping program at Burchell. Nearly 300... Keep Reading...
Eric Sprott Announces Acquisition of Common Shares of Silverco Mining Ltd.

Eric Sprott Announces Acquisition of Common Shares of Silverco Mining Ltd.

Eric Sprott announces that, on October 17, 2025, 2176423 Ontario Ltd., a corporation beneficially owned by him, acquired 4,637,960 common shares (Shares) of Silver Mining Ltd. (Silverco Mining) (being approximately 14.2% of the outstanding Shares) pursuant to the closing of the reverse takeover... Keep Reading...
Prismo Metals Announces Private Placement and Ripsey Gold Project Overlimit Silver Assay Results

Prismo Metals Announces Private Placement and Ripsey Gold Project Overlimit Silver Assay Results

(TheNewswire) NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia TheNewswire - October 20th, 2025 Prismo Metals Inc. (the " Company ") (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce a non-brokered private... Keep Reading...

Latest Press Releases

Related News